Immunovia AB (publ) (IMMVF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.78 Million SEK | -94.54% |
| 2022 | 32.7 Million SEK | 20.42% |
| 2021 | 27.15 Million SEK | -2.97% |
| 2020 | 27.98 Million SEK | -15.5% |
| 2019 | 33.12 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q3 | 21.18 Million SEK | -7.49% |
| 2023 FY | 1.78 Million SEK | -94.54% |
| 2023 Q2 | 22.9 Million SEK | -22.6% |
| 2023 Q1 | 29.58 Million SEK | -9.51% |
| 2023 Q4 | 1.78 Million SEK | -91.57% |
| 2022 Q3 | 35.01 Million SEK | -1.7% |
| 2022 FY | 32.7 Million SEK | 20.42% |
| 2022 Q1 | 36.06 Million SEK | 32.81% |
| 2022 Q2 | 35.61 Million SEK | -1.24% |
| 2022 Q4 | 32.7 Million SEK | -6.6% |
| 2021 Q1 | 31.68 Million SEK | 13.21% |
| 2021 FY | 27.15 Million SEK | -2.97% |
| 2021 Q4 | 27.15 Million SEK | -5.29% |
| 2021 Q3 | 28.67 Million SEK | -5.04% |
| 2021 Q2 | 30.19 Million SEK | -4.7% |
| 2020 Q3 | 30.9 Million SEK | 1.21% |
| 2020 Q1 | 31.85 Million SEK | -3.83% |
| 2020 Q4 | 27.98 Million SEK | -9.42% |
| 2020 FY | 27.98 Million SEK | -15.5% |
| 2020 Q2 | 30.53 Million SEK | -4.16% |
| 2019 Q1 | 30.15 Million SEK | 0.0% |
| 2019 Q4 | 33.12 Million SEK | -4.52% |
| 2019 Q2 | 29.24 Million SEK | -3.01% |
| 2019 FY | 33.12 Million SEK | 0.0% |
| 2019 Q3 | 34.68 Million SEK | 18.61% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 6000.00 USD | -29683.333% |
| Arrayit Corporation | - USD | -Infinity% |
| Atlantic International Corp. | 1.29 Million USD | -37.725% |
| Biocept, Inc. | 10.37 Million USD | 82.776% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 51.3 Million USD | 96.517% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 61.22 Million USD | 97.081% |
| HTG Molecular Diagnostics, Inc. | 546.32 Thousand USD | -227.095% |
| iMD Companies, Inc. | 1.1 Million USD | -61.915% |
| IDenta Corp. | 428.17 Thousand USD | -317.352% |
| Interpace Biosciences, Inc. | 4.24 Million USD | 57.884% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | - USD | -Infinity% |
| Lumos Diagnostics Holdings Limited | - USD | -Infinity% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 278 Thousand USD | -542.806% |
| NovelStem International Corp. | 3.32 Million USD | 46.249% |
| Optigenex Inc. | 4.42 Million USD | 59.635% |
| PharmChem, Inc. | - USD | -Infinity% |
| Proteome Sciences plc | 1.63 Million USD | -9.565% |
| Response Genetics, Inc | 4.91 Million USD | 63.664% |
| Rennova Health, Inc. | 359.19 Thousand USD | -397.504% |
| RushNet, Inc. | 4.25 Million USD | 57.977% |
| ScreenPro Security Inc. | 249.05 Thousand USD | -617.527% |
| Stella Diagnostics Inc. | 798.44 Thousand USD | -123.811% |
| StageZero Life Sciences Ltd. | 576.38 Thousand USD | -210.037% |
| Todos Medical Ltd. | 33 Million USD | 94.585% |